GLUEMonte Rosa Therapeutics, Inc.
$10.32+63% 1Y
$10.32
$6.3352 weeks$25.31
The financials
Monte Rosa Therapeutics, Inc. by the numbers
Monte Rosa Therapeutics, Inc. (GLUE) reported revenue of $9.0M in Q2 2026 (quarter ended Jun 30, 2026), down 61% from the same quarter a year earlier. That came with net loss of $43M. For the full year FY2025, revenue was $124M (+64% year on year) and net income −$39M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $9.0M | $23M | −61% |
| Operating income | −$49M | −$16M | n/a |
| Net income | −$43M | −$12M | n/a |
| Diluted EPS | −$0.43 | −$0.15 | n/a |
On our screens:Most shorted stocks